JP2003509378A - ＩＬ−１ｒａとＩＬ−１プロセシング・放出阻害化合物の併用療法 - Google Patents

ＩＬ−１ｒａとＩＬ−１プロセシング・放出阻害化合物の併用療法

Info

Publication number
JP2003509378A
JP2003509378A JP2001523022A JP2001523022A JP2003509378A JP 2003509378 A JP2003509378 A JP 2003509378A JP 2001523022 A JP2001523022 A JP 2001523022A JP 2001523022 A JP2001523022 A JP 2001523022A JP 2003509378 A JP2003509378 A JP 2003509378A
Authority
JP
Japan
Prior art keywords
alkyl
urea
hydroxy
aryl
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001523022A
Other languages
English (en)
Japanese (ja)
Inventor
リットマン，ブルース・ヘンリー
ウッドワース，タシャ・ルイス・グッドウィン
ドムブロスキ，マーク・アンソニー
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2003509378A publication Critical patent/JP2003509378A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001523022A 1999-09-14 2000-08-28 ＩＬ−１ｒａとＩＬ−１プロセシング・放出阻害化合物の併用療法 Pending JP2003509378A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14
US60/154,010 1999-09-14
PCT/IB2000/001192 WO2001019390A1 (fr) 1999-09-14 2000-08-28 Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree

Publications (1)

Publication Number Publication Date
JP2003509378A true JP2003509378A (ja) 2003-03-11

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001523022A Pending JP2003509378A (ja) 1999-09-14 2000-08-28 ＩＬ−１ｒａとＩＬ−１プロセシング・放出阻害化合物の併用療法

Country Status (13)

Country Link
EP (1) EP1214087A1 (fr)
JP (1) JP2003509378A (fr)
AR (1) AR033650A1 (fr)
AU (1) AU6464400A (fr)
BR (1) BR0014003A (fr)
CA (1) CA2383026A1 (fr)
CO (1) CO5190701A1 (fr)
EC (1) ECSP003652A (fr)
GT (1) GT200000155A (fr)
PA (1) PA8502901A1 (fr)
PE (1) PE20010685A1 (fr)
TN (1) TNSN00183A1 (fr)
WO (1) WO2001019390A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515952A (ja) * 2016-04-18 2019-06-13 アイエフエム トレ インコーポレイテッド Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
JP2020531453A (ja) * 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619066B2 (en) 2004-04-02 2009-11-17 Amgen Inc. IL-1ra variants
WO2008129288A2 (fr) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides utiles dans le traitement de l'inflammation
EP3578547B1 (fr) * 2015-02-16 2021-05-26 The University of Queensland Sulfonylurées, composés apparentés, et leur utilisation
SG11201806745RA (en) 2016-02-16 2018-09-27 Univ Queensland Sulfonylureas and related compounds and use of same
CA3047336A1 (fr) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Composes chimiques comme inhibiteurs de l'activite interleukine-1
AU2017416068A1 (en) 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
EP3634951A1 (fr) 2017-06-09 2020-04-15 Cadila Healthcare Limited Nouveaux composés de sulfoximine substitués
EP3649112A1 (fr) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3
WO2019008025A1 (fr) 2017-07-07 2019-01-10 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
US11203579B2 (en) 2017-07-24 2021-12-21 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
EP3668840A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
WO2019034693A1 (fr) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
MX2020001778A (es) 2017-08-15 2020-03-24 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida.
WO2019043610A1 (fr) 2017-08-31 2019-03-07 Cadila Healthcare Limited Nouveaux dérivés de sulfonylurées substitués
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
WO2019166619A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
WO2020010143A1 (fr) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Modulateurs de nlrp
PE20211049A1 (es) 2018-07-20 2021-06-04 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
EP3870565A1 (fr) 2018-10-24 2021-09-01 Novartis AG Composés et compositions pour traiter des états associés à l'activité des nlrp
EP3911631A4 (fr) 2019-01-14 2022-09-28 Cadila Healthcare Limited Nouveaux dérivés de sulfonylurées substitués
KR20230015418A (ko) * 2020-05-25 2023-01-31 베이징 브이디제이바이오 컴퍼니 리미티드 인터루킨-1 수용체 길항제 및 이를 포함하는 융합 단백질

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
WO1998032733A1 (fr) * 1997-01-29 1998-07-30 Pfizer Inc. Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (fr) * 1998-08-31 2000-06-07 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515952A (ja) * 2016-04-18 2019-06-13 アイエフエム トレ インコーポレイテッド Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
JP2019518071A (ja) * 2016-04-18 2019-06-27 アイエフエム トレ インコーポレイテッド Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
JP7050751B2 (ja) 2016-04-18 2022-04-08 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
JP2020531453A (ja) * 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア

Also Published As

Publication number Publication date
PE20010685A1 (es) 2001-07-03
EP1214087A1 (fr) 2002-06-19
AU6464400A (en) 2001-04-17
TNSN00183A1 (fr) 2005-11-10
WO2001019390A1 (fr) 2001-03-22
CO5190701A1 (es) 2002-08-29
AR033650A1 (es) 2004-01-07
PA8502901A1 (es) 2002-02-21
CA2383026A1 (fr) 2001-03-22
BR0014003A (pt) 2002-05-21
ECSP003652A (es) 2002-04-23
GT200000155A (es) 2002-03-08

Similar Documents

Publication Publication Date Title
JP2003509378A (ja) ＩＬ−１ｒａとＩＬ−１プロセシング・放出阻害化合物の併用療法
US6433009B1 (en) Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
EP2588459B1 (fr) Composés agissant au niveau de plusieurs récepteurs de prostaglandines pour donner une réponse anti-inflammatoire générale
JP2005512522A5 (fr)
KR20030017611A (ko) 중성 엔도펩티다제 억제제로서 시클로펜틸-치환된글루타르아미드 유도체
JP2004522710A (ja) 性機能障害の治療
Auvynet et al. ECL1i, d (LGTFLKC), a novel, small peptide that specifically inhibits CCL2‐dependent migration
JP2004339232A (ja) ジアリールスルフォニルウレア化合物
US20030143230A1 (en) Combination of an IL-1/18 inhibitor with a TNF inhibitor for the treatment of inflammation
JPH111477A (ja) １，４−ベンゾジアゼピン誘導体及びその用途
US20050053603A1 (en) Drugs for liver diseases
WO2001026671A1 (fr) Procedes de traitement au moyen d'inhibiteurs doubles de metalloproteinase-2 matricielle et de metalloproteinase-9 matricielle
EP2945932B1 (fr) Composés ayant un effet sur plusieurs récepteurs des prostaglandines et produisant une réponse anti-inflammatoire générale
EP1270554A1 (fr) Dérivés de sulfonylurée et leur emploi dans le contrôle de l'activité de l'interleukine-1
JP2002516605A (ja) 糖尿病および肥満の治療のための併用療法
JP2003012626A (ja) アルキルアミド化合物
JP2000086533A (ja) 新規なアレルギー治療剤
US20050064519A1 (en) Methods of using GST-Omega-2
MXPA99007030A (en) Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
CZ312799A3 (cs) Přípravky pro modulaci reakce na kortikosteroidy

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060606